Allworth Financial LP Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Allworth Financial LP lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 54.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 604 shares of the biotechnology company’s stock after purchasing an additional 214 shares during the period. Allworth Financial LP’s holdings in BioMarin Pharmaceutical were worth $58,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BMRN. KB Financial Partners LLC lifted its position in shares of BioMarin Pharmaceutical by 51.3% in the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 118 shares during the period. ICA Group Wealth Management LLC purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $31,000. Acadian Asset Management LLC lifted its position in shares of BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 344 shares during the period. Castleview Partners LLC purchased a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $35,000. Finally, MayTech Global Investments LLC purchased a new stake in BioMarin Pharmaceutical during the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the completion of the transaction, the insider now owns 212,117 shares of the company’s stock, valued at $18,068,126.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the completion of the transaction, the insider now owns 212,117 shares of the company’s stock, valued at $18,068,126.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey Robert Ajer sold 4,000 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $87.07, for a total transaction of $348,280.00. Following the completion of the transaction, the executive vice president now directly owns 94,047 shares of the company’s stock, valued at approximately $8,188,672.29. The disclosure for this sale can be found here. Over the last quarter, insiders sold 83,229 shares of company stock valued at $7,237,767. Corporate insiders own 1.84% of the company’s stock.

Analyst Upgrades and Downgrades

BMRN has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Canaccord Genuity Group reissued a “hold” rating and set a $91.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 29th. Robert W. Baird decreased their target price on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a research report on Tuesday, January 30th. Royal Bank of Canada reissued a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $101.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $107.61.

BioMarin Pharmaceutical Trading Up 0.8 %

Shares of BioMarin Pharmaceutical stock opened at $92.22 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The firm has a fifty day moving average price of $87.46 and a 200 day moving average price of $89.07. BioMarin Pharmaceutical Inc. has a 1 year low of $76.02 and a 1 year high of $100.38. The stock has a market cap of $17.40 billion, a PE ratio of 104.80, a price-to-earnings-growth ratio of 1.75 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The firm had revenue of $646.21 million during the quarter, compared to analysts’ expectations of $639.53 million. During the same quarter last year, the company posted $0.11 earnings per share. The firm’s revenue was up 20.2% compared to the same quarter last year. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 1.93 earnings per share for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.